Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
PrincipalTel Aviv, Israel
PartnerTel Aviv, Israel
SupportTel Aviv, Israel
Improve International Ltd. has been acquired by RJD Partners
Benchmark Holdings Plc. has sold Improve International Ltd. to RJD Partners.Learn more
Zemach Hammerman Ltd. has issued bonds
Zemach Hammerman Ltd. has raised funds to refinance the company for further development.Learn more
Mutigny Resort Hotel has raised funds to construct a new 4-star hotel in Champagne
Mutigny Resort Hotel (MRH) has raised funds to construct a new 4-star hotel in Champagne. This involved agreements with the promoter, Artec Groupe, the operator, Loisium Wine & Spa Hotels, bank debt with Caisse d'Epargne Grand-Est Europe, Banque Postale and Arkea, and equity with La Banque des territoires, Merimee and Artec Groupe.Learn more